老年IgA肾病患者的临床特征与预后
这项回顾性多中心研究分析了1990至2015年间西班牙151例≥65岁经活检证实的IgA肾病患者,发现诊断率随时间显著上升,无症状尿检异常和AKI为主要表现,部分血尿相关AKI与抗凝治疗有关,整体预后较差。
要点
- 老年IgA肾病诊断率近年显著增加,抗凝治疗可能部分解释此趋势。
- 无症状尿检异常最常见,其次为AKI,其中多数为血尿相关AKI。
- 年龄、就诊时血肌酐和肾活检间质纤维化程度与不良结局相关。
核心结论
- 西班牙老年人群中IgA肾病诊断逐渐增加,抗凝治疗可能部分导致此趋势。
- 老年IgA肾病患者预后较差,5年无复合终点生存率仅26%。
研究设计与样本
- 回顾性多中心研究,纳入1990至2015年诊断为活检证实的IgA肾病且年龄≥65岁的151例患者。
主要发现
- 诊断例数从1990-1995年的6例增至2011-2015年的62例(趋势P=0.03)。
- 无症状尿检异常84例(55%),AKI 61例(40%),其中血尿相关AKI 53例(86%),新月体性IgA肾病8例,肾病综合征6例(4%)。
- 血尿相关AKI中18例(34%)使用口服抗凝药,在大于72岁的34例中该比例升至42%。
- 无复合终点生存率1年74%、2年48%、5年26%。
- 年龄、就诊时血清肌酐和肾活检间质纤维化程度与结局显著相关,使用肾素-血管紧张素-醛固酮阻断剂与较低风险相关,免疫抑制治疗与结局无显著相关。
临床怎么用
- 老年IgA肾病患者应评估抗凝药物使用与血尿相关AKI的风险。
- 肾活检间质纤维化程度和就诊时血肌酐可用于风险分层。
局限性
- 回顾性多中心设计可能引入选择偏倚和信息偏倚。
- 样本来自西班牙单一国家人群,外推性需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Some studies suggest that the incidence of IgA nephropathy is increasing in older adults, but there is a lack of information about the epidemiology and behavior of the disease in that age group. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In this retrospective multicentric study, we analyzed the incidence, forms of presentation, clinical and histologic characteristics, treatments received, and outcomes in a cohort of 151 patients ≥65 years old with biopsy-proven IgA nephropathy diagnosed between 1990 and 2015. The main outcome was a composite end point of kidney replacement therapy or death before kidney replacement therapy. RESULTS: We found a significant increase in the diagnosis of IgA nephropathy over time from six patients in 1990-1995 to 62 in 2011-2015 (P value for trend =0.03). After asymptomatic urinary abnormalities (84 patients; 55%), AKI was the most common form of presentation (61 patients; 40%). Within the latter, 53 (86%) patients presented with hematuria-related AKI (gross hematuria and tubular necrosis associated with erythrocyte casts as the most important lesions in kidney biopsy), and eight patients presented with crescentic IgA nephropathy. Six (4%) patients presented with nephrotic syndrome. Among hematuria-related AKI, 18 (34%) patients were receiving oral anticoagulants, and this proportion rose to 42% among the 34 patients older than 72 years old who presented with hematuria-related AKI. For the whole cohort, survival rates without the composite end point were 74%, 48%, and 26% at 1, 2, and 5 years, respectively. Age, serum creatinine at presentation, and the degree of interstitial fibrosis in kidney biopsy were risk factors significantly associated with the outcome, whereas treatment with renin-angiotensin-aldosterone blockers was associated with a lower risk. Immunosuppressive treatments were not significantly associated with the outcome. CONCLUSIONS: The diagnosis of IgA nephropathy among older adults in Spain has progressively increased in recent years, and anticoagulant therapy may be partially responsible for this trend. Prognosis was poor. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2019_07_16_CJASNPodcast_19_08_.mp3.
引用
- Sevillano AM, Diaz M, Caravaca-Fontán F, et al. IgA Nephropathy in Elderly Patients. Clin J Am Soc Nephrol. 2019. PMID: 31311818. doi:10.2215/CJN.13251118
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。